174 related articles for article (PubMed ID: 38439048)
1. Microfluidics-enabled fluorinated assembly of EGCG-ligands-siTOX nanoparticles for synergetic tumor cells and exhausted t cells regulation in cancer immunotherapy.
Han X; Zhang G; Wu X; Xu S; Liu J; Wang K; Liu T; Wu P
J Nanobiotechnology; 2024 Mar; 22(1):90. PubMed ID: 38439048
[TBL] [Abstract][Full Text] [Related]
2. Synergetic regulation of cancer cells and exhausted T cells to fight cold tumors with a fluorinated EGCG-based nanocomplex.
Zhang J; Wang M; He D; Zhang L; Liu T; Wang K
J Nanobiotechnology; 2023 Nov; 21(1):420. PubMed ID: 37957632
[TBL] [Abstract][Full Text] [Related]
3. Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy.
Wu P; Zhang H; Yin Y; Sun M; Mao S; Chen H; Deng Y; Chen S; Li S; Sun B
Adv Sci (Weinh); 2022 May; 9(15):e2105894. PubMed ID: 35486032
[TBL] [Abstract][Full Text] [Related]
4. Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier-Free Nanoassembly of Fluorinated Prodrug and siRNA.
Wu P; Zhang H; Sun M; Mao S; He Q; Shi Y; Deng Y; Dong Z; Xu Q; Zhao C; Zhang W; Sun B
Adv Mater; 2022 Sep; 34(38):e2203019. PubMed ID: 35918816
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of EGCG and melittin with self-assembled fluoro-nanoparticles for enhanced cancer therapy.
Sun M; Wu Y; Zhou Z; Liu S; Mao S; Li G
Aging (Albany NY); 2023 Jun; 15(11):4875-4888. PubMed ID: 37277118
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
[TBL] [Abstract][Full Text] [Related]
7. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
8. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
9. Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy.
Tang Y; Chang Q; Chen G; Zhao X; Huang G; Wang T; Jia C; Lu L; Jin T; Yang S; Cao L; Zhang X
Biomater Adv; 2023 Jul; 150():213425. PubMed ID: 37084635
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
12. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
13. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
14. A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells.
Barati M; Mirzavi F; Atabaki M; Bibak B; Mohammadi M; Jaafari MR
Int Immunopharmacol; 2022 Oct; 111():109022. PubMed ID: 35987146
[TBL] [Abstract][Full Text] [Related]
15. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
16. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
17. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
18. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
[TBL] [Abstract][Full Text] [Related]
19. Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review.
Zhou Z; Wang H; Li J; Jiang X; Li Z; Shen J
Int J Biol Macromol; 2024 Jan; 254(Pt 2):127911. PubMed ID: 37939766
[TBL] [Abstract][Full Text] [Related]
20. Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy.
Xie F; Tang S; Zhang Y; Zhao Y; Lin Y; Yao Y; Wang M; Gu Z; Wan J
ACS Nano; 2024 Jan; 18(2):1690-1701. PubMed ID: 38165832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
